VCU Massey researchers uncover process that drives prostate cancer metastasis

(Virginia Commonwealth University) Researchers at VCU Massey Cancer Center have uncovered a novel function of the gene PLK1 (polo-like kinase 1) that helps prostate cancer cells metastasize (spread) to other parts of the body. This mechanism highlights new potential targets for cancer therapies and challenges the previous understanding of PLK1's role in cancer growth and progression.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses Data On Racial Differences In Response To Novel Prostate Cancer Therapies. At The 2019 Genitourinary Can... Author: obr Added: 03/20/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
(MedPage Today) -- Patient preference assessment tool aligns with pros and cons of prostate cancer therapies
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
GP Abstract The impact of sex hormones on anticancer immunity deserves attention due to the importance of the immune system in cancer therapy and the recognition of sex differences in immunity. Cancer is ultimately the result of failed immune surveillance and diverging effects of male and female sex hormones on anticancer immunity could contribute to the higher cancer incidence and poorer outcome in men. Estrogens and androgens affect the number and function of immune cells, an effect that depends on cell type, tumor microenvironment, and the age and reproductive status of the individual. Despite the recent progr...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Authors: Zhao L, Zhou S, Gustafsson JÅ Abstract Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human physiology and pathology, serving as sensors of stimuli, master regulators of downstream molecular events and hubs governing complex gene regulatory networks. The importance of various members of the NR superfamily in cancer has led to substantial efforts to target them therapeutically. Notably, drugs that block the action of estrogen receptor alpha (ERα) in patients with ERα+ breast cancer or the androgen receptor (AR) in prostate cancer patients have provid...
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research
Conclusion: The study did not support an overall effect of postdiagnosis low-dose aspirin use on prostate cancer mortality. However, results for extended exposure periods suggest that low-dose aspirin use might be inversely associated with prostate cancer mortality after 5 years from cancer diagnosis. Primary Funding Source: Danish Cancer Society. PMID: 30831581 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tags: Ann Intern Med Source Type: research
Publication date: Available online 1 March 2019Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Nada Zabaiou, Allan Fouache, Amalia Trousson, Julio Buñay-Noboa, Geoffroy Marceau, Vincent Sapin, Ahmed Zellagui, Silvère Baron, Mesbah Lahouel, Jean-Marc A. LobaccaroAbstractAntiandrogens have a peculiar place in the treatment of metastatic prostate cancer by blocking the androgen receptor (AR). Unfortunately, aggressive tumors could rapidly develop into a castration resistant state. It is therefore essential to look for new molecules that are more effective, affecting not only the andro...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
VIENNA - PET/MRI with the radiopharmaceutical gallium-68 (Ga-68) prostate-specific...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA-11 PET/MRI benefits prostate cancer patients Ga-68 PSMA-11 PET/MRI advances prostate cancer detection Gallium-labeled PET tracer could advance cancer detection SNMMI letter urges FDA to ease shortage of gallium-68 SNMMI: Early prostate cancer therapy extends lives
Source: Headlines - Category: Radiology Source Type: news
UCLA scientists have developed a new method to quickly screen hundreds of drugs in order to identify treatments that can target specific tumors.The approach could help scientists understand how a person ’s tumor would respond to a certain drug or drug combination, and it could help guide treatment decisions for people with rare and hard-to-treat cancers. Apaper detailing the new technique was published in Communications Biology.“We always focus on how we need new and better drugs to treat cancer,” said Alice Soragni, the senior author of the study and a scientist at the UCLA Jonsson Comprehensive Can...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
A shorter radiotherapy protocol for treating prostate cancer is comparable...Read more on AuntMinnie.comRelated Reading: ASTRO: AI's rad therapy future is in predicting outcomes ASTRO: SBRT works well for less risky prostate cancer ASTRO releases new prostate radiation therapy guideline SNMMI: Early prostate cancer therapy extends lives Hypofractionated RT works for prostate cancer
Source: Headlines - Category: Radiology Source Type: news
Abstract The evolution of therapeutic resistance is a major cause of death for cancer patients. The development of therapy resistance is shaped by the ecological dynamics within the tumor microenvironment and the selective pressure of the host immune system. These selective forces often lead to evolutionary convergence on pathways or hallmarks that drive progression. Thus, a deeper understanding of the evolutionary convergences that occur could reveal vulnerabilities to treat therapy-resistant cancer. To this end, we combined phylogenetic clustering, systems biology analyses, and molecular experimentation to ident...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Med Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Prostate Cancer